Mr William Jorgensen

NHMRC Peter Doherty Early Career Research Fellow

F11 - Chemistry Building
The University of Sydney

Telephone +61 2 8627 8778
Fax +61 2 9351 3329

Curriculum vitae Curriculum vitae

Biographical details

William Jorgensen is an early career researcher at the University of Sydney.

Following his PhD conferral from The Univerisity of Sydney in 2017, Will worked as a drug discovery consultant within the pharmaceutical industry. He was involved in the implementation of pre-clinical/clinical programs for the JAPAC region.

He was awarded an NHMRC Peter Doherty Early Career Fellowship in 2019 and returned to The University of Sydney to initiate his independant career.

Research interests

Research in the Jorgensen Group is focussed on the synthesis and analysis of CNS active therapeutics that target ion channel receptors with the potential to treat neurological disorders. The projects Will offers are segments of a broader multi-disciplinary research focus starting with rational based drug design and ending with behavioural neuroscience.

Such projects include:

  • The design and synthesis of GABAA receptor modulators for the treatment of neuroinflammation
  • The synthesis of Glycine receptor modulators for the treatment of neuropathic pain and associated disorders

Awards and honours

2019: NHMRC Peter Doherty Fellowship

Selected grants

2019

  • The development of ion channel modulators for the treatment of neurological disorders; Jorgensen W; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gulliver, D., Werry, E., Reekie, T., Katte, T., Jorgensen, W., Kassiou, M. (2019). Targeting the oxytocin system: New pharmacotherapeutic approaches. Trends In Pharmacological Sciences, 40(1), 22-37. [More Information]
  • Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2018). Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin-and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 143, 1644-1656. [More Information]
  • Callis, T., Reekie, T., O'Brien-Brown, J., Wong, E., Werry, E., Elias, N., Jorgensen, W., Tsanaktsidis, J., Rendina, L., Kassiou, M. (2018). The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 74(12), 1207-1219. [More Information]
  • Katte, T., Reekie, T., Werry, E., Jorgensen, W., Boyd, R., Wong, E., Gulliver, D., Connor, M., Kassiou, M. (2017). Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 136, 330-333. [More Information]
  • Jorgensen, W., Gulliver, D., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2016). Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. European Journal of Medicinal Chemistry, 108, 730-740. [More Information]
  • Katte, T., Reekie, T., Jorgensen, W., Kassiou, M. (2016). The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. The Journal of Organic Chemistry, 81(11), 4883-4889. [More Information]
  • Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C., Kassiou, M., Hunt, G., McGregor, I. (2012). The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor-Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 24(7), 1012-1029. [More Information]
  • Banister, S., Moussa, I., Jorgensen, W., Chua, S., Kassiou, M. (2011). Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 21(12), 3622-3626. [More Information]
  • Banister, S., Moussa, I., Beinat, C., Reynolds, A., Schiavini, P., Jorgensen, W., Kassiou, M. (2011). Trishomocubane as a Scaffold for the Development of Selective Dopamine Transporter (DAT) Ligands. Bioorganic and Medicinal Chemistry Letters, 21(1), 38-41. [More Information]

Patents

  • Jorgensen, W., Munoz, L., Kassiou, M. (2018). CNS permeable anti cancer tubulin inhibitors. Patent No. AU2018900313, AU2018900315.
  • Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Kassiou, M. (2017). Peptide molecules for the treatment of mental illness. Patent No. AU2017903935.
  • Jorgensen, W., Bowen, M., McGregor, I., Werry, E., Reekie, T., Kassiou, M. (2017). Small molecule treatments for mental illness. Patent No. International PCT WO2017004674 A1, International PCT/AU2017/051371.

2019

  • Gulliver, D., Werry, E., Reekie, T., Katte, T., Jorgensen, W., Kassiou, M. (2019). Targeting the oxytocin system: New pharmacotherapeutic approaches. Trends In Pharmacological Sciences, 40(1), 22-37. [More Information]

2018

  • Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2018). Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin-and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 143, 1644-1656. [More Information]
  • Jorgensen, W., Munoz, L., Kassiou, M. (2018). CNS permeable anti cancer tubulin inhibitors. Patent No. AU2018900313, AU2018900315.
  • Callis, T., Reekie, T., O'Brien-Brown, J., Wong, E., Werry, E., Elias, N., Jorgensen, W., Tsanaktsidis, J., Rendina, L., Kassiou, M. (2018). The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 74(12), 1207-1219. [More Information]

2017

  • Katte, T., Reekie, T., Werry, E., Jorgensen, W., Boyd, R., Wong, E., Gulliver, D., Connor, M., Kassiou, M. (2017). Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 136, 330-333. [More Information]
  • Jorgensen, W., Gulliver, D., Katte, T., Werry, E., Reekie, T., Kassiou, M. (2017). Peptide molecules for the treatment of mental illness. Patent No. AU2017903935.
  • Jorgensen, W., Bowen, M., McGregor, I., Werry, E., Reekie, T., Kassiou, M. (2017). Small molecule treatments for mental illness. Patent No. International PCT WO2017004674 A1, International PCT/AU2017/051371.

2016

  • Jorgensen, W., Gulliver, D., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2016). Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. European Journal of Medicinal Chemistry, 108, 730-740. [More Information]
  • Katte, T., Reekie, T., Jorgensen, W., Kassiou, M. (2016). The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. The Journal of Organic Chemistry, 81(11), 4883-4889. [More Information]

2012

  • Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C., Kassiou, M., Hunt, G., McGregor, I. (2012). The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor-Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 24(7), 1012-1029. [More Information]

2011

  • Banister, S., Moussa, I., Jorgensen, W., Chua, S., Kassiou, M. (2011). Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 21(12), 3622-3626. [More Information]
  • Banister, S., Moussa, I., Beinat, C., Reynolds, A., Schiavini, P., Jorgensen, W., Kassiou, M. (2011). Trishomocubane as a Scaffold for the Development of Selective Dopamine Transporter (DAT) Ligands. Bioorganic and Medicinal Chemistry Letters, 21(1), 38-41. [More Information]

To update your profile click here. For support on your academic profile contact .